Aqunova Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 7 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.07 Cr
- Revenue Growth -5.64%
- Profit Growth -9.64%
- Ebitda -194.47%
- Net Worth 15.41%
- Total Assets 8.28%
About Aqunova Pharma
Aqunova Pharma Private Limited (APPL) is a Private Limited Indian Non-Government Company incorporated in India on 20 September 2017 (Seven years and four months 11 days old ). Its registered office is in Ahmedabad, Gujarat, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹1.07 Cr.
Pranshu Kumawat and Ritesh Joshi serve as directors at the Company.
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U52609GJ2017PTC099167
- Company No.
099167
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Sep 2017
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Who are the key members and board of directors at Aqunova Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ritesh Joshi  | Director | 12-Nov-2020 | Current |
| Pranshu Kumawat | Director | 20-Sep-2017 | Current |
Financial Performance of Aqunova Pharma.
Aqunova Pharma Private Limited, for the financial year ended 2022, experienced Minor drop in revenue, with a 5.64% decrease. The company also saw a slight decrease in profitability, with a 9.64% decrease in profit. The company's net worth Soared by an impressive increase of 15.41%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aqunova Pharma?
In 2020, Aqunova Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Lecorps Pharma LlpRitesh Joshi is a mutual person
- Aquwell Pharma Private Limited
Ritesh Joshi is a mutual person
Charges (Loans)
₹10.70 M
₹0
Charges Breakdown by Lending Institutions
- Others : 1.07 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 23 Mar 2023 | Others | ₹0.70 M | Open |
| 08 Jun 2020 | Others | ₹1.00 Cr | Open |
How Many Employees Work at Aqunova Pharma?
Aqunova Pharma has a workforce of 47 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Aqunova Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Aqunova Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
